Rheumatoid Arthritis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH

The Key Rheumatoid Arthritis Companies in the market include - Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others.

The Rheumatoid Arthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Rheumatoid Arthritis pipeline products will significantly revolutionize the Rheumatoid Arthritis market dynamics.

DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Rheumatoid Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Rheumatoid Arthritis Market Insight [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Rheumatoid Arthritis Market Report:

*
The Rheumatoid Arthritis market size was valued approximately ~USD 29 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA Registered (guselkumab) for children aged six years and older weighing at least 40 kg with moderate to severe plaque psoriasis (PsO) who are eligible for systemic therapy or phototherapy, as well as for active psoriatic arthritis (PsA). This approval marks TREMFYA Registered as the first and only IL-23 inhibitor authorized for these pediatric indications, expanding upon its prior FDA approvals for adults with moderate to severe plaque PsO in 2017 and active PsA in 2020.

*
In April 2025, The European Medicines Agency (EMA) approved Cullinan Therapeutics' clinical trial application for CLN-978, a prospective therapy for rheumatoid arthritis (RA). This Phase I open-label study will include patients with active, treatment-resistant RA, according to the 2010 ACR/EULAR classification criteria. The trial aims to assess the drug's pharmacokinetics, pharmacodynamics, safety, and impact on disease activity.

*
In December 2024, XBiotech's stock experienced a sharp decline following the suspension of its clinical program for rheumatologic diseases. The decision comes as the company works to interpret the results of a Phase II trial evaluating its arthritis therapy, Natrunix, which did not achieve its primary endpoint. The Texas-based biotech cited "significant irregularities" in the trial (NCT05363917), which complicated clear analysis of the data. In response to the trial's inconclusive outcomes, XBiotech has halted all related development efforts. The announcement led to a 27% drop in the company's stock value as investors reacted to the setback.

*
In April 2025, Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company specializing in targeted therapies across multiple modalities, announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) for CLN-978. The upcoming Phase 1 clinical study will evaluate CLN-978 in patients with active and treatment-resistant rheumatoid arthritis who meet the 2010 classification criteria established by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).

*
In February 2025, AnaptysBio has reported encouraging results from its Phase IIb RENOIR trial evaluating rosnilimab for moderate-to-severe rheumatoid arthritis (RA). At week 14, 69% of participants reached low disease activity-marking one of the most robust responses observed to date. The randomized study (NCT06041269) assessed the safety and tolerability of rosnilimab in RA patients who had previously been treated with conventional disease-modifying antirheumatic drugs (DMARDs). The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in disease activity, measured by the mean change from baseline in the 28-Joint Disease Activity Score (DAS28-CRP), compared to placebo.

*
In January 2025, LAPIX Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing innovative oral therapies that restore immune balance in autoimmune disorders via TIM receptor agonism, has announced the first patient has been dosed in its Phase 1b clinical trial (NCT06628206) of LPX-TI641. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, and pharmacokinetics of LPX-TI641 in individuals with moderate-to-severe Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). The trial aims to enroll up to 50 participants, with topline data expected by early third quarter of 2025.

*
Rabeximod has the potential to become a viable treatment option in the rheumatoid arthritis market, as it directly targets a clinical gap by offering beneficial tolerability, a unique mechanism of action, and accessibility for both early and late stages of the disease.

*
As per the World Health Organization (2023), approximately 70% of individuals affected by rheumatoid arthritis are female, and 55% are aged 55 years or older.

*
The collective number of diagnosed prevalent cases of rheumatoid arthritis in the 7MM was estimated to be approximately 4,200,000 in 2023 and is anticipated to rise throughout the study duration.

*
In 2023, the United States reported the highest number of prevalent rheumatoid arthritis cases among the 7MM, with approximately 1,430,000 diagnoses. Additionally, this number is projected to rise throughout the forecast period.

*
In 2023, the age bracket of 55-64 years accounted for the highest number of cases, approximately 450,000, followed by the age group of 65 years and above in the United States.

*
Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others

*
Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others

*
The Rheumatoid Arthritis epidemiology based on gender analyzed that according to Pediatric Rheumatology prevalence rate is consistently higher in girls in comparison to boys

Rheumatoid Arthritis Overview

Rheumatoid Arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function.

Get a Free sample for the Rheumatoid Arthritis Market Report:

https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market [https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rheumatoid Arthritis Market

The dynamics of the Rheumatoid Arthritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2020-2034.

Rheumatoid Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Rheumatoid Arthritis Epidemiology Segmentation:

The Rheumatoid Arthritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Rheumatoid Arthritis

*
Prevalent Cases of Rheumatoid Arthritis by severity

*
Gender-specific Prevalence of Rheumatoid Arthritis

*
Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis

Download the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rheumatoid Arthritis market or expected to get launched during the study period. The analysis covers Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Rheumatoid Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Rheumatoid Arthritis Therapies and Key Companies

*
OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

*
RINVOQ (upadacitinib): AbbVie

*
Rabeximod (Rob 803): Cyxone

*
Imvotamab: IGM Biosciences

*
Sarilumab (Kevzara): Regeneron/Sanofi

*
Baricitinib: Eli Lilly and Company

*
Certolizumab pegol: UCB BIOSCIENCES GmbH

*
Upadacitinib: AbbVie

*
Tofacitinib: Pfizer

*
Sarilumab SAR153191 (REGN88): Sanofi

*
GenaKumab: Changchun GeneScience Pharma

*
AIN457: Novartis

*
Etanercept: Istituto Giannina Gaslini

To know more about Rheumatoid Arthritis treatment, visit @ Rheumatoid Arthritis Medications [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rheumatoid Arthritis Market Drivers

*
Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Rheumatoid Arthritis

*
Population rates of social anxiety disorder in children and young people have been investigated in several countries

*
Many therapies are under investigation in various phases of clinical trials

Rheumatoid Arthritis Market Unmet Needs

*
Challenge in recognition of condition

*
Development of novel therapies

*
Limited availability in services

*
Poor disease understanding

*
Development of effective treatment

Scope of the Rheumatoid Arthritis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others

*
Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others

*
Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies

*
Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Rheumatoid Arthritis Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement

Discover more about therapies set to grab major Rheumatoid Arthritis market share @ Rheumatoid Arthritis market forecast [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Rheumatoid Arthritis Market Report Introduction

2. Executive Summary for Rheumatoid Arthritis

3. SWOT analysis of Rheumatoid Arthritis

4. Rheumatoid Arthritis Patient Share (%) Overview at a Glance

5. Rheumatoid Arthritis Market Overview at a Glance

6. Rheumatoid Arthritis Disease Background and Overview

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Rheumatoid Arthritis

9. Rheumatoid Arthritis Current Treatment and Medical Practices

10. Rheumatoid Arthritis Unmet Needs

11. Rheumatoid Arthritis Emerging Therapies

12. Rheumatoid Arthritis Market Outlook

13. Country-Wise Rheumatoid Arthritis Market Analysis (2020-2034)

14. Rheumatoid Arthritis Market Access and Reimbursement of Therapies

15. Rheumatoid Arthritis Market Drivers

16. Rheumatoid Arthritis Market Barriers

17. Rheumatoid Arthritis Appendix

18. Rheumatoid Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rheumatoid-arthritis-market-to-experience-notable-growth-in-forecast-span-by-2034-delveinsight-predicts-abbvie-pfizer-regeneronsanofi-eli-lilly-and-company-ucb-biosciences-gmbh]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.